CymaBay looks to raise $85M as liver drug’s PhIII readout looms

Bay Area biotech CymaBay Therapeutics is looking to start the year with more cash in its pockets.

CymaBay announced on Tuesday that it is planning to sell 10,000,000 shares of common stock at $7.00 per share. If all goes well, the sale is expected to bring...

Click to view original post